Deals this week: AMAG Pharmaceuticals, Noxxon Pharma, Teewinot Life Sciences


US-based biopharmaceutical company AMAG Pharmaceuticals intends to raise $250m in gross proceeds through an underwritten public offering of convertible senior notes.

Underwriters will also be granted a 30-day option to purchase notes for a principal amount up to an additional $37.5m in order to cover any over-allotments.

Due 1 June 2022, the notes will help raise funds required for the company to repay its borrowings under its credit facility.

German biopharmaceutical company Noxxon Pharma has raised €10m ($10.9m) in gross proceeds through a private placement of ODIRNANE bonds, which are convertible into new shares and / or exchangeable for existing shares.

The company has also issued BSA share warrants for up to €10m ($10.9m) in multiple tranches.

It has concurrently raised €1m ($1.09m) through the private placement of 64,512 shares if its common stock priced at €15.5 ($16.9) a share.

The proceeds are intended to be used for general corporate purposes, as well as the clinical development of its drug candidate NOX-A12, which targets advanced solid tumours.

"Teewinot Life Sciences has completed a series B financing round led by Tuatara Capital to raise $12.3m."

Teewinot Life Sciences has completed a series B financing round led by Tuatara Capital to raise $12.3m.

The proceeds will be used for enhancing and accelerating research and development (R&D), expanding business and acquiring patents.

US-based Teewinot is engaged in the discovery, development and commercialisation of cannabinoid-based therapeutics.

EPI Group’s subsidiary EPI Health has acquired Cipher Pharmaceuticals’s commercial assets in the US.

EPI Health is based in the US, while Cipher Pharmaceuticals is based in Canada. The sale helps Cipher to focus on speciality pharmaceuticals.

The transaction involved a cash consideration of $13.6m.

Beijing Biostar Technologies intends to conduct a private placement of shares to raise ¥50m ($7.25m).

Betta Pharmaceuticals has agreed to subscribe to the placement and will, as a result, own 4.5% stake in the issuing company.

Based in China, Beijing Biostar Technologies provides anti-cancer drugs.